Metronidazole is now being used with increasing frequency for various infectious conditions in patients with renal failure. It is commonly administered to septic patients who have developed acute renal failure requiring hemodialysis. The hemodialysis clearances of metronidazole and its metabolites were evaluated in nine renal failure patients on maintenance hemodialysis. The mean ± standard deviation clearance and the extraction ratio were 106.9 ± 16.3 ml/min and 0.65 ± 0.08, respectively, when regenerated cellulose dialysis membrane was used. The clearance and the extraction ratio with the use of cuprophan membrane were 72.1 ± 17.3 ml/min and 0.44 ± 0.12, respectively. The clearances and extraction ratios for the metabolites were similar to those of the parent drug. For both metronidazole and the hydroxy metabolite, the clearance and the extraction ratio demonstrated a statistically significant difference between the regenerated cellulose membrane and the cuprophan membrane. In summary, metronidazole and its metabolites were found to be highly dialyzable with different clearances depending on the specific type of membrane used. However, owing to the relatively wide therapeutic index of the drug, dosage supplementation may be necessary only in seriously ill patients to ensure therapeutic effect.
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Metronidazole is a nitroimidazole derivative introduced into clinical usage more than 20 years ago, originally for the treatment of Trichomonas vaginalis infection. Its use was subsequently expanded to include treatment of amebiasis and giardiasis. More recently, metronidazole has been recognized to be effective in treating sepsis secondary to certain susceptible anaerobic organisms (1, 11) . On the basis of these developments, the growing popularity of metronidazole has resulted in increased use of the drug in hemodialysis patients. Some of these patients have acute renal failure; others have chronic renal failure. Both groups of patients may require the drug for a variety of infectious conditions. Information on the effect of hemodialysis on the pharmacokinetics of metronidazole is, therefore, necessary to optimize treatment for these patients. Removal of the drug by the dialysis procedure may compromise therapeutic efficacy; on the other hand, overzealous dosage replacement may result in toxicities. This study was designed to evaluate the hemodialysis clearance of metronidazole and its metabolites.
MATERIALS AND METHODS Subjects. The study was conducted at the University of Illinois Hospital, and it was approved by the Institutional Review Board of the University of Illinois. Nine renal failure patients who required hemodialysis treatment participated in the study. Six of the patients received metronidazole for the treatment of infections (subjects 1 to 6). The remaining three chronic hemodialysis patients volunteered to receive metronidazole (subjects 7 to 9). The patient characteristics and indications for hemodialysis are shown in Table 1 . None of the subjects was known to have a history of hypersensitivity reaction to metronidazole or its analogs. Subjects were also excluded if they had consumed alcohol within 48 h of the study period or if they were receiving any alcohol-containing medications (e.g., elixir). Patients on coumadin therapy were also excluded, owing to potential drug interaction with metronidazole.
Drug administration. In subjects 1 to 6, who received metronidazole therapy (Searle Pharmaceutical Inc., Chicago, Ill.), the decision to initiate drug treatment and the dosage were determined by their primary physicians. Doses (500 mg) of the drug were commonly administered intravenously or orally during the interdialytic period.
For the three subjects who volunteered to receive metronidazole (subjects 7 to 9), an oral dose of 750 mg was given 12 h before hemodialysis treatment. An additional intravenous dose of 500 mg was administered to each of these three subjects through the venous line of the dialyzer at the beginning of the hemodialysis session. The combined oral and intravenous doses were designed to yield therapeutic drug concentration during hemodialysis and to allow time for metabolite production.
Dialysis setup. A Centry delivery system (COBE Laboratories, Lakewood, Colo.) was used to control blood and dialysate flow. The dialysate was made from a 1:35 dilution of Hemodialysis Bath Concentrate (Renal System Inc., Minneapolis, Minn.). The dialysate flow rate was maintained at 575 ml/min, and drug clearances were evaluated at a blood flow rate of 150 to 250 ml/min. The characteristics of the dialyzer membrane (regenerated cellulose [Cordis Dow Inc., Miami Lakes, Fla.] or cuprophan [Terumo Corp., Piscataway, N.J.]) and the blood flow rate are shown in Table 2 .
Sample collection and assay. Blood sample pairs were obtained simultaneously from the arterial and venous lines of the dialyzer. The specimens were drawn at least 1 h after the beginning of hemodialysis treatment to allow adequate time for distribution of the drug. Subsequent drug concentration in serum should then follow a linear decline. Blood sample pairs were obtained approximately 30 min apart, and the sampling was conducted during a single hemodialysis treatment in all subjects except subjects 1, 4, and 6. In these three subjects, the specimens were collected in two different dialysis sessions.
Heparinized VACUTAINER tubes (Becton Dickinson Vacutainer Systems, Rutherford, N.J.) were used to collect the blood specimens. The samples were then centrifuged, and the sera were kept frozen at -10°C until assayed for drug concentrations. A small sample of arterial blood was also obtained at the time of each blood drawing for hematocrit determination. High-performance liquid chromatography was used to determine concentrations of metronidazole and the hydroxy and acidic metabolites (12) . The coefficients of variation of the assay results were between 2 and 8%. During the early phase of the study, only the concentrations of the parent drug were determined in subjects 1 and 2. Clearance calculation. Hemodialysis clearances of metronidazole and its metabolites were calculated by using the relationship CLD = [QB (1 -Hct) (CA -Cv)]/CA, in which CLD is the hemodialysis clearance, QB is the rate of blood flow through the dialysis machine, Hct is the hematocrit, CA is the concentration in serum at the arterial side, and Cv is the concentration in serum at the venous side of the dialysis machine.
The extraction ratios (ERs) were determined as follows:
RESULTS Hemodialysis clearances and extraction ratios of metronidazole and of the hydroxy metabolite are shown in Table 2 . The metronidazole clearances and extraction ratios with the use of regenerated cellulose membrane (group 1) were higher than those for the cuprophan membrane (group 2). The mean ± standard deviation clearance and extraction ratio for the regenerated cellulose membrane were 106.9 ± 16.3 ml/min and 0.65 ± 0.08, respectively. In contrast, clearance and extraction ratio for the cuprophan membrane were 72.1 ± 17.3 ml/min and 0.44 ± 0.12, respectively. Student's t test revealed a statistically significant difference for these parameters between the two types of membranes (P < 0.001).
The mean ± standard deviation hemodialysis clearance and extraction ratio of the hydroxy metabolite for the regenerated cellulose membrane were 120.1 ± 5.2 ml/min and 0.59 ± 0.03, respectively. For the cuprophan membrane, the clearance and the extraction ratio were 68.7 ± 18.1 ml/min and 0.42 ± 0.12, respectively. A statistically significant difference exists between the two types of membranes for both clearance (P < 0.01) and extraction ratio (P < 0.03).
The concentration of the acidic metabolite was below the detectable limit of the assay in all of the subjects except subject 3. The dialysis clearance and the extraction ratio of the acidic metabolite in this subject were 121.2 ± 12.2 ml/min and 0.60 ± 0.06, respectively, using the regenerated cellulose membrane.
DISCUSSION
Pharmacotherapeutic decisions in hemodialysis patients often require special consideration. The lack of renal function may alter drug disposition, and the dialysis treatment will affect the pharmacokinetics of most drugs. Metronidazole is extensively metabolized by the liver. Renal elimination is responsible for the excretion of the unchanged drug and its major metabolites (5) . In patients with poor renal function, the half-life of the drug is similar to that in patients with normal kidney function. However, the half-life of the hydroxy metabolite has been reported to be prolonged (3). Gabriel hydroxy metabolite in plasma rapidly decreased to the subtherapeutic range during treatment (2) . This observation suggested that the dialysis procedure removed a substantial amount of the parent drug and the hydroxy metabolite. However, the hemodialysis clearances of these compounds were not measured in their study, thus precluding the applicability of their observations. In our study, we showed that metronidazole is extensively removed by hemodialysis and that the mean hemodialysis clearances were approximately 70 to 110 ml/min, depending on the membrane used. This type of clearance is not unexpected for metronidazole, which has a molecular weight of 170 and exhibits minimal serum protein binding (11) . The drug should be able to cross most dialysis membranes without much difficulty. The hydroxy metabolite was also found to be dialyzable, with clearances and extraction ratios similar to that of the parent drug. Because the serum half-life of the hydroxy metabolite is prolonged in patients with renal failure (3) , chronic dosing of the drug may result in accumulation of the metabolite. This was considered to be a potential cause for toxicity in a patient receiving metronidazole (9) . The results of our study indicate that the hydroxy metabolite is also highly dialyzable, and the risk of accumulation in the hemodialysis patient is thus minimized.
Comparison of dialysis clearances and extraction ratios for both the parent drug and the metabolite revealed statistically significant differences between the two types of dialyzer membranes. The clearances for metronidazole with the regenerated cellulose membrane were approximately 50% higher than those of the cuprophan membrane (Table 2) . Of interest is the fact that the two types of membranes had very similar urea and creatinine clearances despite the differences in surface areas (Table 3 ). This lack of correlation with metronidazole clearances may be related to the differences in configurations and physicochemical properties between metronidazole and the urea and creatinine molecules. In contrast, variations in membrane pore size, thickness, and other characteristics may be responsible for the striking difference in metronidazole clearances between dialyzers. It is important to know that the urea and creatinine clearances did not correlate with the clearances of metronidazole and the hydroxy metabolite; hence, they should not be used to predict drug clearance unless such a relationship is established a priori.
Roux et al., using Travenol twin-coil dialyzers (8) , recently reported that the clearances of metronidazole and the metabolites were approximately 60 ml/min. These values are slightly lower than those we observed using hollow fiber dialyzers. However, twin-coil dialyzers are now infrequently used in most dialysis centers (10) . In another study, by Kreeft et al., the mean metronidazole hemodialysis clearance in five patients was 61.7 ml/min (6) . The clearances with the cuprophan membrane in three of the patients they studied were slightly higher than those of the two patients with polyacrylonitrile membrane, despite a lower rate of blood flow in the first group of patients. Their results further demonstrate the variations in metronidazole clearances related to the use of different dialysis membranes. If clearances are used as guidelines for drug dosing without consideration of the specific type of membrane that the patient will be using, these differences between dialyzers may result in a drastic error in the dosage determination.
All the currently available information indicates that metronidazole is removed by hemodialysis treatment; our study further demonstrated that the hydroxy metabolite is dialyzable. Although the potential of serum concentration rebound 
